Special Issue

Host Response and Immunity to Influenza A Virus Infection

Message from the Guest Editors

Respiratory infectious diseases, especially influenza viruses and coronaviruses, pose a substantial risk to humans due to their rapid transmission, the lack of effective universal vaccines, and the diversity in host immune responses. Influenza A viruses are highly contagious in birds, animals and humans, and frequently spillover to cause pandemics in human populations. Understanding the influenza viruses' ability to escape the immune system; identifying host factors impacting immunity; deepening our knowledge on immune responses, immune diversity, biological sex differences impacting virus pathogenesis and immune response; and developing mAbs that provide broad protection against influenza viruses are critically important to prevent influenza virus pandemics and epidemics. This Research Topic aims to represent research studies on influenza virus pathogenesis, virus-host interactions. genetic diversity and evolution of influenza A viruses, intra-host dynamics, antiviral countermeasures and immune responses, vaccine effectiveness, variations in individual responsiveness to vaccination, and vaccination strategies.

Guest Editors

Dr. Faten A. Okda

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA

Dr. Ahmed Kandeil

Centre of Scientific Excellence for Influenza Viruses, National Research Centre, Dokki, Giza 12622, Egypt

Deadline for manuscript submissions

closed (30 April 2024)



an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/155251

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

